abrdn Life Sciences Investors
HQL
69 hedge funds and large institutions have $71.2M invested in abrdn Life Sciences Investors in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
114% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 14
42% more capital invested
Capital invested by funds: $50M → $71.2M (+$21.2M)
13% more funds holding
Funds holding: 61 → 69 (+8)
3.4% more ownership
Funds ownership: 14.54% → 17.94% (+3.4%)
Top Buyers
Top Sellers
HQL Hedge Fund Activity: Q4 2019 in Review
69 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q4 2019, worth a combined $71.2M — up 42% from $50M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new HQL positions and 6 closed out — a net gain of 8 holders — while 30 added to existing stakes and 14 trimmed.
The largest buyer was Karpus Investment Management, opening a new position worth an estimated $2.22M. The largest seller was Private Advisor Group, exiting entirely with an estimated $1.36M sold.
- 69 institutional investors held abrdn Life Sciences Investors (HQL) as of Q4 2019, up from 61 in Q3 2019.
- Funds reported $71.2M of abrdn Life Sciences Investors stock for Q4 2019, up 42% quarter-over-quarter.
- 14 funds opened new abrdn Life Sciences Investors positions in Q4 2019 and 6 closed out, a net change of +8 holders.
- The largest abrdn Life Sciences Investors buyer in Q4 2019 was Karpus Investment Management, an estimated $2.22M added.
- The largest abrdn Life Sciences Investors seller in Q4 2019 was Private Advisor Group, an estimated $1.36M sold.
Based on aggregated 13F filings for Q4 2019.